Invenra launched its B-Body Express Antibody Expression service, which enables biotechnology and pharmaceutical companies to rapidly access the company’s B-Body bispecific antibody platform, the company announced recently. “Advancing bispecific programs…
Promega has partnered with EditCo Bio, a leader in engineered cell solutions, offering high-quality, functionally validated CRISPR-edited cell lines, the company announced recently. “This agreement accelerates scientific innovation by providing…
SHINE Technologies and Modawina Medical Company (MMC) have entered a strategic distribution partnership to bring Ilumira, SHINE’s non-carrier-added lutetium-177, to patients in the United Arab Emirates, the company announced recently….
Exact Sciences has launched Oncodetect, a new test designed to detect molecular residual disease (MRD) across multiple solid tumors, the company announced today. “Exact Sciences is transforming cancer care by…
Promega’s HiBiT-PsVLP Bioassay will be used in the development of vaccines for infectious viral diseases and help support a collaboration between Charles River and the Coalition for Epidemic Preparedness Innovations’…
SHINE Technologies is partnering with Sumitomo Corporation of Americas (SCOA), a leading global trading and investment company, the company announced today. According to a release, the partnership, formalized through a…
Presentations, Pitches 4-5:30 p.m. Tuesday, April 8 at Elvehjem Building – UW Madison School of Computer, Data & Information Sciences: RED Talks: Virtually Unwrapping the Herculaneum Scrolls 6-8 p.m. Tuesday,…
Exact Sciences has launched Cologuard Plus, a next-generation, noninvasive colorectal cancer screening text, the company announced today. According to a release, the Cologuard Plus test detects 95% of colorectal cancers…
Exact Sciences and Flatiron Health, a healthtech company dedicated to improving cancer care and advancing research, are partnering to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease test…
Invenra and Orion Corporation, a globally operating pharmaceutical company, announced recently that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform. “This collaboration highlights…
